Infliximab for Crohn's disease in the Swiss IBD Cohort Study: clinical management and appropriateness
ContributorsJuillerat, Pascal; Pittet, Valerie; Vader, John-Paul; Burnand, Bernard; Gonvers, Jean-Jacques; De Saussure, Philippe Pierre Hubert; Mottet, C.; Seibold, F.; Rogler, G.; Sagmeister, M.; Felley, Christian; Michetti, P.; Froehlich, F.; Swiss IBD Cohort Study Group
CollaboratorsTempia-Caliera Schaeppi, Michela
Published inEuropean journal of gastroenterology & hepatology, vol. 22, no. 11, p. 1352-1357
Publication date2010
Abstract
Keywords
- Adolescent
- Adult
- Anti-Inflammatory Agents/*therapeutic use
- Antibodies, Monoclonal/*therapeutic use
- Crohn Disease/diagnosis/*drug therapy
- Female
- Gastrointestinal Agents/*therapeutic use
- Guideline Adherence
- Humans
- Male
- Patient Selection
- Practice Guidelines as Topic
- Predictive Value of Tests
- Prospective Studies
- Severity of Illness Index
- Switzerland
- Treatment Outcome
- Young Adult
Research group
Citation (ISO format)
JUILLERAT, Pascal et al. Infliximab for Crohn’s disease in the Swiss IBD Cohort Study: clinical management and appropriateness. In: European journal of gastroenterology & hepatology, 2010, vol. 22, n° 11, p. 1352–1357.
Main files (1)
Article
Identifiers
- PID : unige:21030
- PMID : 20964261
ISSN of the journal0954-691X